Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 9/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 9/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 9/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL892987 | 0.86 | LMNA (1.00) | LMNACHRM1CHRM2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL9093331 | 0.83 | LMNA (0.93) | LMNACHRM1CHRM2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL3757253 | 0.83 | LMNA (0.93) | LMNACHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL9733197 | 0.83 | LMNA (0.93) | LMNACHRM1CHRM2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL6081619 | 0.83 | LMNA (0.93) | LMNACHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL3274800 | 0.78 | POLB (0.50) | LMNACHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL21540333 | 0.76 | — | — | |
| SCHEMBL20507245 | 0.75 | LMNA (0.67) | LMNACHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL3162750 | 0.75 | LMNA (0.77) | LMNACHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL964866 | 0.74 | LMNA (0.74) | LMNACHRM1CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625908-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | disclosed |
| US-20070244136-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015743-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ABL1, EGFR | LMNA 3500/4885CHRM1 4685/4885CHRM2 4779/4885 |
| US-20070244136-A1 | Quinazoline Derivatives | ERBB2, ABL1, MKI67 | LMNA 3865/4885CHRM1 1919/4885CHRM2 2392/4885 |
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ABL1, ERBB2, LCK | LMNA 4401/4885CHRM1 2601/4885CHRM2 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.